<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453414</url>
  </required_header>
  <id_info>
    <org_study_id>C200-007</org_study_id>
    <nct_id>NCT00453414</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension</brief_title>
  <official_title>Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of iloprost for PAH in
      children who are between the ages of 3 and 18 years old.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn due to lack of enrollment
  </why_stopped>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">October 2006</completion_date>
  <primary_completion_date type="Anticipated">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 6-minute walk distance measured post-inhalation (for patients ≥ 8 years old) at Week 8 and Week 16</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Borg Dyspnea Scale measured following 6-MWT (for patients ≥ 8 years old) at Week 8 and Week 16</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in NYHA/WHO functional class at Week 8 and Week 16</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in hemodynamic parameters measured at Week 16, and in patients who are able to undergo iloprost inhalation while consciously sedated, hemodynamic parameters measured prior to dosing and 15-30 minutes after dosing</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to clinical worsening, defined as any one of the following: death due to underlying PAH, transplantation, atrial septostomy, hospitalization for PAH or right heart failure, &gt;15% worsening in 6-minute walk distance in concert with a ≥ 1 class deteri</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Child Health Questionnaire (CHQ-28) at Week 8 and Week 16</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in exercise capacity, as measured by post-inhalation CPET, at Week 8 and Week 16 (if ≥ 8 years old and &gt; 130 cms in height. CPET testing will be conducted on NYHA/WHO Class IV patients at the discretion of the Principal Investigat</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost Inhalation Solution (Ventavis)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 3-18 years

          -  Diagnosis of PAH due to IPAH, connective tissue disease, or congenital heart disease

          -  Pulmonary arterial hypertension confirmed by a cardiac catheterization, with mPAP &gt; 25
             mmHg at rest, PCWP or LVEDP ≤ 15 mmHg, and PVR ≥ 240 dynes/sec/cm-5 (ie, ≥ 3.0 units
             m2)

          -  NYHA/WHO functional Class II, III, or IV

          -  Have had a 6-minute walk test (6-MWT) performed within the 3 months preceding the
             screening visit (if ≥ 8 years of age)

          -  Have had cardiopulmonary exercise testing (CPET) performed within the 3 months
             preceding the screening visit (if ≥ 8 years of age and &gt; 130 cms in height. CPET
             testing will be conducted on NYHA/WHO Class IV patients at the discretion of the
             Principal Investigator)

          -  If receiving therapy for PAH, on a stable dose and regimen for at least 3 months prior
             to the screening visit

          -  If receiving digoxin, diuretic, or oxygen therapy, on a stable dose and regimen for at
             least 30 days preceding the screening visit

          -  Must demonstrate the ability to appropriately use the nebulizer device as part of the
             screening process

        Exclusion Criteria:

          -  Prior use of prostacyclins or prostacyclin analogues within 3 months prior to
             screening

          -  Portal hypertension or clinically relevant hepatic disease

          -  Eisenmenger syndrome with resting SpO2 &lt;88% on room air

          -  Clinically relevant asthma or other chronic lung disease, such as bronchopulmonary
             dysplasia, cystic fibrosis, or repaired or unrepaired congenital diaphragmatic hernia

          -  Diagnosis or current evidence of active lung infection or clinically relevant
             hemoptysis

          -  Left-sided heart disease, including valvular disease or heart failure

          -  Initiation or dosage adjustment of PAH-specific therapy within 3 months prior to
             screening

          -  Initiation of treatment with digoxin, diuretics, anticoagulation, or oxygen therapy
             within 30 days prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Children's Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2007</study_first_posted>
  <last_update_submitted>February 12, 2010</last_update_submitted>
  <last_update_submitted_qc>February 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2010</last_update_posted>
  <keyword>PAH</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

